About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

CCHR: NIH Must Fully Probe Psychiatric Drug Links to Violence for Public Safety

News Source: Citizens Commission on Human Rights

LOS ANGELES, Calif., Sept. 10, 2025 (SEND2PRESS NEWSWIRE) — Families and communities deserve answers about the potential role psychiatric drugs may play in senseless acts of violence—an issue suppressed for decades by vested interests. The Citizens Commission on Human Rights International (CCHR) is urging that the National Institutes of Health (NIH) study on psychotropic drugs and violence be given the full weight it deserves, warning that dismissing it would betray the public’s right to safety and truth.

CCHR: Communities deserve answers on the potential role psychotropic drugs and treatments may have in senseless acts of violence
Image caption: Communities deserve answers on the potential role psychotropic drugs and treatments may have in senseless acts of violence – an issue too long suppressed by vested interests.

The NIH has been directed to investigate studies to shed light on the link between psychiatric drugs, particularly SSRI (Selective Serotonin Reuptake Inhibitor) antidepressants, and violence.

CCHR President Jan Eastgate stressed: “The significance of this lies in its potential to open a conversation long silenced—how mind-altering drugs, prescribed to millions, may contribute to acts of senseless violence, from shootings to stabbings and assaults that devastate families.”

Cocaine, methamphetamine, and alcohol are widely recognized as risk factors for aggression. “Why should prescription psychotropics be treated differently? Families deserve truth, not excuses,” Eastgate added.

Tennessee in 2025 mandated toxicology testing for psychotropic drugs in autopsies after certain mass shootings—a landmark policy CCHR says should be expanded nationwide to cover all mass acts of violence.[1] A Florida Senator has announced plans to file a bill requiring disclosure of whether perpetrators of mass or terroristic violence had taken antidepressants, citing public safety concerns.

In 2000, the New York State Senate proposed tracking violent crimes committed by individuals tested for psychotropic drugs. The bill stalled in committee, but had it passed, a reporting system would already be in place.

Concerns are not new. In 1989, at a Kentucky coroner’s inquest, a psychiatrist testified that an antidepressant influenced a workplace shooting in which eight people were killed. Since then, medical experts across the U.S. and internationally have raised alarm over violent acts linked to psychiatric drugs, while the industry has resisted scrutiny.

Regulators have long issued warnings:

  • The Food and Drug Administration (FDA) has logged at least 1,530 reports of homicide or homicidal ideation associated with psychiatric drugs.
  • FDA advisories (2004, 2005) highlighted risks of agitation, hostility, and suicidal behavior on antidepressants. It also warns of homicidal ideation with one SSRI.[2]
  • Health Canada warned of SSRIs’ “potential for harm, including suicidal thoughts and the onset or worsening of agitation-type adverse events.”[3]
  • Australian regulators linked stimulants such as dextroamphetamine and atomoxetine to homicidal thoughts.[4]
  • The European Medicines Agency reported increased aggression in children and adolescents taking SSRIs.[5]
  • FDA Black Box Warnings already acknowledge suicidal thoughts on drugs such as the ADHD drug Strattera (atomoxetine hydrochloride) and antidepressants.

The Violence Project’s Mass Shooter Database reports at least 24% of shooters had been on psychotropics—a figure likely underestimated due to limited access to medical records.[6] Independent researchers, including Professors Peter C. Gøtzsche and David Healy, have published data showing increased aggression linked to SSRIs.[7]

The FDA admitted in 2007 that all patients on antidepressants should be closely monitored for agitation, hostility, aggression, or unusual behavior.[8] Professor Healy has explained that drug-induced agitation is a major causal factor in suicide and violence, with about 5% of patients dropping out of trials for this reason—ten times the placebo rate.[9] Applied to 45 million Americans on antidepressants, that risk could potentially affect 2.25 million people.

Withdrawal adds further risks. The UK Royal College of Psychiatrists warns that stopping antidepressants can trigger anger, agitation, suicidal impulses, or akathisia—an intense inner restlessness linked to violence. These effects may persist for weeks, months, or longer.[10] “Too often, such reactions are misrepresented by vested interests as a perpetrator merely stopping treatment, rather than serious drug-induced withdrawal effects,” Eastgate said.

Recent tragedies highlight the issue:

  • S. and European incidents in 2025 revealed perpetrators with histories of psychiatric drug treatment or active prescriptions.
  • Investigators in Sweden concluded that one mass killer acted under the influence of amphetamine and sedative drugs.
  • Reports from Tennessee, Florida, New York, and Germany similarly documented psychiatric drugs in connection with acts of mass violence.

While not every individual reacts violently, evidence shows that a subset does—and families deserve to be informed of the risks.

Violence is not a symptom of mental illness. As Dr. Jonathan Metzl of Vanderbilt University notes, no psychiatric diagnosis includes homicidal behavior. Substance-induced states, however, are well-recognized causes of violence.

Other influences also matter. Programs such as “death education” and court-mandated anger management have shaped violent behavior in some cases. Two U.S. school shooters in Columbine, Colorado—one taking an SSRI—had been instructed in class to imagine and write about their own deaths. One described a shooting spree—then weeks later, enacted it.[11]

Eastgate emphasized: “Investigating this issue does not mean excusing crime. It means transparency, accountability, and willingness to examine all possible causes, rather than protecting commercial interests. To ignore prescription psychotropics despite regulatory warnings and clinical evidence is reckless.”

CCHR argues that honest inquiry is essential:

  • Families who lost loved ones deserve clear answers.
  • Communities living in fear need prevention strategies grounded in science, not industry spin.
  • Policymakers must have accurate data to legislate effectively.

CCHR has published a documented report, Psychiatric Drugs: Create Violence & Suicide—School Shootings and Other Acts of Senseless Violence.

CCHR is a non-profit mental health industry watchdog founded in 1969 by the Church of Scientology and professor of psychiatry, Dr. Thomas Szasz. For more than five decades, it has investigated and exposed psychiatric abuse, leading to reforms and protections worldwide.

To learn more, visit: https://www.cchrint.org/2025/09/09/nih-study-on-psychiatric-drugs-and-violence-must-not-be-dismissed/

Sources:

[1] https://www.thegatewaypundit.com/2025/04/ablechild-tennessee-sets-national-precedent-passage-ablechild-bill/

[2] “Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – Nov. 2005

[3] https://www.canada.ca/en/news/archive/2004/06/health-canada-advises-canadians-stronger-warnings-ssris-other-newer-anti-depressants.html

[4] Australian Therapeutic Goods Administration “Product Information safety updates”

[5] Ibid.

[6] https://www.theviolenceproject.org/mass-shooter-database/

[7] https://www.madinamerica.com/2024/08/violence-caused-by-antidepressants-ignored-once-again-by-psychiatrists/; https://www.eventbrite.com/e/antidepressants-and-homicide-automatism-spectrum-disorders-tickets-1020994190107

[8] https://www.cchrint.org/2024/10/11/cchr-wants-increased-consumer-awareness-about-prescriptions-for-violence/; https://www.bmj.com/content/358/bmj.j3697

[9] https://www.bmj.com/content/358/bmj.j3697

[10] https://www.cchrint.org/2021/04/06/antidepressant-withdrawal-warning-vital/; https://www.researchgate.net/publication/335329642_Antidepressant_withdrawal_-_the_tide_is_finally_turning

[11] https://www.washingtontimes.com/news/2002/aug/18/20020818-040825-5515r/

MULTIMEDIA:

Image link for media: https://www.Send2Press.com/300dpi/25-0910-s2p-cchracts-300dpi.jpg

Image caption: Communities deserve answers on the potential role psychotropic drugs and treatments may have in senseless acts of violence – an issue too long suppressed by vested interests.


This press release was issued on behalf of the news source (Citizens Commission on Human Rights), who is solely responsible for its accuracy, by Send2Press Newswire.

To view the original story, visit: https://www.send2press.com/wire/cchr-nih-must-fully-probe-psychiatric-drug-links-to-violence-for-public-safety/

Copr. © 2025 Send2Press® Newswire, Calif., USA. -- REF: S2P STORY ID: S2P129192 FCN24-3B

 

INFORMATION BELOW THIS PAGE, IF ANY, IS UNRELATED TO THIS PRESS RELEASE.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.